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Gene transfer may be preventive but not curative for a lysosomal
transport disorder
Abstract
Cystinosis belongs to a growing class of lysosomal storage disorders (LSDs) caused by defective
transmembrane proteins. The causative CTNS gene encodes the lysosomal cystine transporter,
cystinosin. Currently the aminothiol cysteamine is the only drug available for reducing cystine storage
but this treatment has non-negligible side effects and administration constraints. In this study, for the
first time, we report viral vector-mediated CTNS gene transfer and evaluate the feasibility of this
strategy as a complementary treatment. Initially, we transduced human CTNS(-/-) fibroblast cell lines
and primary murine Ctns(-/-) hepatocyte cultures in vitro and demonstrated that gene transfer can reduce
cystine storage. Because of age-related increase in cystine levels, we transduced hepatocytes from
young (</=3 months of age) and older (>/=5 months of age) mice. Our in vitro data suggested that the
efficiency of correction was age-dependent. We tested these observations in vivo: short-term (1 week)
and long-term (4 weeks) CTNS-transduction significantly reduced hepatic cystine levels in young, but
not older, Ctns(-/-) mice. Our data provide the proof-of-concept that gene transfer is feasible for
correcting defective lysosomal transport, but suggest that, in the case of cystinosis, it could be
preventive but not curative in some tissues.
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 ABSTRACT  
Fibroblast growth factor-2 (FGF2) is a potent angiogenic growth factor. Here, gene 
expression profiling of FGF2-stimulated microvascular endothelial cells revealed, together 
with a prominent pro-angiogenic profile, a pro-inflammatory signature characterized by the 
upregulation of pro-inflammatory cytokine/chemokines and their receptors, endothelial cell 
adhesion molecules, and members of the eicosanoid pathway. Real time quantitative PCR 
demonstrated early induction of most of the FGF2-induced, inflammation-related genes. 
Accordingly, chick embryo chorioallantoic membrane (CAM) and murine Matrigel plug 
angiogenesis assays evidenced a significant monocyte/macrophage infiltrate in the areas 
of FGF2-driven neovascularization. Similar results were obtained when the conditioned 
medium of FGF2-stimulated endothelial cells was delivered onto the CAM, suggesting that 
FGF2-upregulated chemoattractants mediate the inflammatory response. Importantly, 
FGF2-triggered new blood vessel formation was significantly reduced in 
phosphatidylinositol 3-kinase-γ null mice exhibiting defective leukocyte migration or in 
clodronate liposome-treated, macrophage-depleted mice. Furthermore, the viral pan-
chemokine antagonist M3 inhibited the angiogenic and inflammatory responses induced by 
the conditioned medium of FGF2-stimulated endothelial cells and impaired FGF2-driven 
neovascularization in the CAM assay. These findings point to inflammatory chemokines as 
early mediators of FGF2-driven angiogenesis and indicate a nonredundant role for 
inflammatory cells in the neovascularization process elicited by the growth factor.  
 2
 INTRODUCTION  
 
Angiogenesis and inflammation are closely integrated processes in a number of 
physiological and pathological conditions, including wound healing, psoriasis, diabetic 
retinopathy, rheumatoid arthritis, arteriosclerosis, and cancer1-3. Inflammatory cells, such 
as monocytes/macrophages, neutrophils, platelets, mast cells, and lymphocytes, may 
produce angiogenic cytokines, growth factors, and proteases that contribute to the 
formation of new vascular structures at the site of inflammation, tissue damage, or tumor 
growth3,4. Conversely, microvascular endothelium activated by a number of cytokines and 
angiogenic growth factors can express pro-inflammatory molecules involved in leukocyte 
recruitment and activation5,6. Strikingly, neovascularization and inflammation share a 
number of common signaling pathways and molecular mediators, the cyclooxigenase 
(Cox)/prostaglandin pathway representing a paradigm of this convergence7. Also, various 
chemokines may act both as leukocyte attractants and as angiogenic inducers by acting 
directly on endothelial cells8,9. Moreover, a number of pro-inflammatory cytokines [e.g. 
interleukin-1α (IL-1α), IL-1ß, IL-6, tumor necrosis factor-α (TNFα), high mobility group 
box-1 (HMGB1), and osteopontin (Opn)] may induce blood vessel formation via direct 
engagement of target endothelial cells or indirectly by inducing leukocytes and/or 
endothelial cells to produce pro-angiogenic mediators10-12. Conversely, the angiogenic 
factors vascular endothelial growth factor (VEGF) and angiopoietin-1 (Ang-1) may elicit 
pro-inflammatory responses in endothelial cells by upregulating the expression of cell 
adhesion molecules and inflammatory mediators13,14. 
Fibroblast Growth Factor 2 (FGF2) is a pleiotropic heparin-binding factor that promotes 
growth and differentiation of a broad spectrum of cell types15. FGF2 exerts a potent 
angiogenic response in a variety of in vivo animal models, including the chick embryo 
chorioallantoic membrane (CAM) assay, the rodent cornea assay, and the s.c. Matrigel 
plug assay in mice15. In vitro, FGF2 triggers a complex “pro-angiogenic phenotype” in 
endothelial cells that recapitulates the neovascularization process. It consists in the 
degradation of the extracellular matrix following protease upregulation, and endothelial 
cell migration, proliferation, and morphogenesis. Also, FGF2 regulates the expression of 
cadherins, integrins, and various extracellular matrix components that contribute to the 
maturation of the new blood vessels15. These responses are mediated by the interaction 
of FGF2 with high-affinity tyrosine kinase FGF receptors (FGFRs) and low-affinity 
heparan sulfate proteoglycans and integrin receptors, leading to the activation of multiple 
 3
signal transduction pathways, including phospholipase C-γ, phosphatidylinositol 3-kinase 
(PI3K), and mitogen-activated protein kinases15,16.  
Elevated levels of FGF2 have been implicated in the pathogenesis of several diseases 
characterized by a deregulated angiogenic/inflammatory response, including cancer 
15,17,18. Inflammatory cells, including mononuclear phagocytes, T lymphocytes, and mast 
cells, express FGF2. Moreover, FGF2 production and release from endothelial cells are 
triggered by inflammatory mediators (reviewed in15. Conversely, experimental evidences 
indicate that FGF2 amplifies the endothelial cell response to various inflammatory 
stimuli19, induces nitric oxide-mediated vasoactive effects20, and upregulates the 
expression of Opn12, Ccl2 chemokine21,22, and cyclooxigenase 2 (Cox-2)23 in endothelial 
cells. Taken together, these observations point to the existence of a tight cross-talk 
between inflammatory and angiogenic responses during FGF2-driven neovascularization. 
Here, we report that FGF2 induces the expression of a wide repertoire of inflammation-
related genes in murine microvascular endothelial cells, including pro-inflammatory 
cytokines/chemokines and their receptors, endothelial cell adhesion molecules, and 
components of the prostanglandin pathway. Consistent with this pro-inflammatory 
signature, we provide in vivo evidence about the non-redundant role of chemokines and 
infiltrating monocytes/macrophages in FGF2-driven neovascularization. 
 
MATERIALS AND METHODS 
 
Cells and Reagents. Murine lung microvascular endothelial cells (1G11 cells)24 were 
obtained from A. Vecchi (Instituto Ricerche Farmacologiche Mario Negri, Milan, Italy). 
1G11 cells were cultured in Dulbecco modified Eagle medium (DMEM) containing 20% 
inactivated fetal bovine serum (FBS). For stimulation with FGF2, cells were usually 
starved for 24 hours with DMEM containing 0.5% FBS before stimulation with the growth 
factor.  
Recombinant 18 kDa FGF2 was purified from transformed Escherichia coli as previously 
described25. Ketoprofen and hydrocortisone were purchased from Sigma-Aldrich (Saint 
Louis, MO). 
 
Affymetrix GeneChip analysis. For oligonucleotide microarray analysis, three 
independent 1G11 cell cultures were stimulated for 10 hours with 30 ng/mL FGF-2 in 
DMEM supplemented with 0.5% FBS. As a control reference, duplicate samples from 
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non-treated cells were also analyzed. RNA extraction, reverse transcription, cRNA 
preparation and GeneChip hybridization were performed according to the manufacturer’s 
instructions (Affymetrix, Santa Clara, CA). A detailed protocol can be found at 
http://www.affymetrix.com/support/technical/manual/expression_manual.affx. 
In brief, total RNA was extracted using Trizol (Invitrogen Life technologies, USA) and 
phase lock gels (Eppendorf; Hamburg, Deutschland). RNA was further purified with 
Rneasy columns (Qiagen, Valencia, CA). Ten µg of purified RNA were the used as a 
template for double-stranded cDNA synthesis primed using a T7-(dT)24 oligonucleotide. 
Double-stranded cDNA was then in vitro transcribed using T7 RNA polymerase to 
produce biotin-labeled cRNA. Resulting cRNA was fragmented and hybridized to 
Affymetrix GeneChip Murine Genome MOE430A oligonucleotide microarrays containing 
22,690 probe sets, corresponding approximately to 15,000 genes. 
To define the transcriptional profile modulated by FGF2, raw expression measures at the 
probe level data were computed using Robust Multi-array Average (RMA). Quantile 
normalization was performed across all microarrays to achieve the same distribution of 
signal intensities for each array (Irizarry, Bolstad). Data analysis was then carried out 
using Genespring 7.2 software (Silicon Genetics, Redwood City, CA). Initial data filtering 
of genes with a "present" detection call in at least 20% of genechips, according to 
Affymetrix MAS5 algorithm,  was applied. Differential expression was assessed by Welch-
modified two sample t-test (p<0.05) using a cross-gene error model. Type II error was 
controlled by applying a False Detection Rate (FDR) of 5%. FGF2-regulated genes were 
subsequently filtered by applying a fold change cutoff of 2.0.  
FGF2-regulated genes were annotated by employing the web-accessible softwares 
DAVID (Database for Annotation, Visualization and Integrated Discovery; 
http://david.niaid.nih.gov/) and NetAffx Analysis Center (http://www.Affymetrix) which 
provides functional genomic annotations for Gene Ontology (GO), protein domain, and 
biological pathways. Over-represented signatures, based on GO terms (cellular 
localization, molecular function and biological process), were identified using statistical 
Fisher's test (p<0.05) and the whole MOE430A gene list as the reference list. The 
complete, Minimum Information About a Microarray Experiment (MIAME)–compliant 
dataset is available at the Gene Expression OmnibusXX (reference no. GSEXXXX)  
 
Real-time PCR analysis. Two-step quantitative RT-PCR (qRT-PCR) was employed to 
validate microarray expression data. Random-primed RT was carried out with 50 ng of 
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RNA and High-Capacity cDNA Archive Kit (Applied Biosystems, Foster City, CA). 
Reactions lacking enzyme were carried out in tandem for each RNA sample as negative 
controls. One-fiftieth of the final RT reaction was used as template in qRT-PCR reactions 
containing HPLC-purified oligonucleotide primers (Thermo Electron, Ulm, Germany) 
specific for selected genes.  
Primers were designed with Primer3 software (http://frodo.wi.mit.edu/cgi-
bin/primer3/primer3_www_slow.cgi) using the following settings: 100-200 bp PCR 
products, 18-22mer primers, 60°C melting temperatures. Gene names, accession 
numbers, and forward and reverse primer sequences are listed in Supplementary Table 1 
with the only exception for the Cxcl1 gene that was analyzed by using a Gene Expression 
Assay (Mm00433859_m1) from Applied Biosystems and the manufacturer's TaqMan® 
PreAmp Master Mix Kit Protocol. Each primer set produced a single product, as 
determined by melt-curve analysis. Real-time PCR was carried out on a iCycler Real-
Time PCR Detection System (BioRad) using 25-µL reactions containing iQ SYBR Green 
Supermix, 150-300 nM forward and reverse primers, and 5 µL of cDNA-diluted template. 
The PCR cycling profile was as follows: 3 minutes at 95°C and 40 cycles for 15 seconds 
at 95°C, 60°C for 1 minute. After PCR amplification, melting curve analysis was 
performed for each reaction 
Each PCR reaction was performed in triplicate on one plate and fluorescence data were 
recorded using iCycler software (BioRad). Relative expression ratios were calculated by 
use of Pfaffl equation and Relative Expression Software Tool (http://www.gene-
quantification.info). The mRNA expression levels of target genes were normalized to the 
levels of β-actin gene, which, according to microarray experiments, behaves as a 
housekeeping gene under the tested conditions. 
 
Endothelial Cell Adhesion to FGF2-coated plastic dishes. Adhesion of endothelial 
1G11 cells to FGF2-coated plastic dishes was performed as described26 with minor 
modifications. Non-tissue polystyrene culture plastic 35 mm dishes were incubated with 
100 mM NaHCO3, pH 9.6 (carbonate buffer) containing 5 µg/mL of human recombinant 
FGF2. After 16 hours of incubation at 4°C, the dishes were washed three times with cold 
carbonate buffer and two times with DMEM containing 0.5 % FBS.  
For the cell adhesion assay, 100,000 1G11 cells, previously starved in DMEM containing 
0.5 % FBS for 24 hours, were seeded onto 35-mm FGF2-coated dishes and incubated for 
24 hours at 37°C in 1 mL DMEM containing 0.5 % FBS. Cells were dissociated in Trizol 
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for RNA extraction followed by qRT-PCR. The conditioned medium from FGF2-stimulated 
cells was collected and stored at -20°C until use in chemotaxis assays. As negative 
control, 1G11 cells were seeded on tissue polystyrene culture plastic plates (35-mm 
diameter) and processed as before. For comparison purposes, confluent cultures of 1G11 
cells, previously starved for 24 hours in DMEM containing 0.5 % FBS, were treated with 
30 ng/mL of free human recombinant FGF2 for an additional 24-hour period and 
processed as before. 
Human FGF2 content in the conditioned media from unstimulated and FGF2-stimulated 
cells were tested by ELISA using the Immunoassay kit from Biosource International (CA, 
USA). 
 
Chemotaxis assay. Human monocytes were obtained from buffy coats of healthy blood 
donors by Ficoll (Lympholite-H, Cederlane Labs) and Percoll (Amersham Biosciences) 
gradients. Chemotaxis was assayed in 96 well-plates (Neuro Probe Inc., Gaithersburg, 
MD) containing a polycarbonate filter with 5 µm pores. Briefly, monocytes were washed 
twice and resuspended in RPMI-1640 medium containing 1% serum, and then loaded 
onto inserts at 5 x 103 cells/50 µL for each well. 30 µL of RPMI-1640 medium containing 
the chemoattractants at the indicated concentrations were placed in the bottom 
compartment. After 1.5 hours of incubation at 37°C with 5% CO2, nonmigrating cells were 
scraped from the upper surface of the filter. Migrating cells on the lower surface were 
fixed with methanol and stained with Diff-Quik (Baxter Healthcare, Miami, FL). The 
number of monocytes on the lower surface of the filter was determined by counting 5 
microscopic fields per well at x 250 magnification. For inhibitory assays, cells and media 
were preincubated for 30 minutes with the indicated concentrations of the pan-chemokine 
inhibitor M3 before loading onto Transwell inserts. Each sample was tested in triplicate. 
 
In vivo Matrigel plug angiogenesis assay. Liquid Matrigel (10 mg/ml; 0.5 ml/mouse) 
mixed at 4°C with FGF2 (1.0 µg/mL), M3 (500 nM) or both, was injected subcutaneously 
into the flank of 6 week-old C57BL/6 mice (Charles River, Calco, Italy), where it quickly 
gelified.  Matrigel with PBS alone was used as negative control. Alternatively, 5-week-old 
129sv WT and 129sv PI3Kγ-/- mice27 were used. On day 7 after implantation, mice were 
sacrificed and plugs were removed, embedded in Tissue Tec OCT (Sigma-Aldrich, Saint 
Louis, MO), snap-frozen by immersion in liquid nitrogen-cooled isopentane, and stored at 
 7
-80°C. Alternatively, pellets were fixed in 3.7% formaldehyde-PBS, paraffin embedded, 
and processed for histological analysis as described below.  
 
Macrophage depletion. Six week-old C57BL/6 mice were injected intraperitoneally with 
clodronate liposomes (Clodro-lip) or PBS liposomes (PBS-lip) every 4 days (initial dose 
1.5 mg/20 g-mouse, then every 4th day 0.8 mg/20 g-mouse) for four weeks. During the 
fourth week of treatment, macrophage depleted 9 week-old mice were used for FGF2-
Matrigel assay as described above. Mice were sacrificed by cervical dislocation 3 days 
after the last clodronate liposome injection. 
 
Histological and immunofluorescence analysis. Haematoxylin/eosin (H&E) staining 
was performed on paraffin-embedded 5 µm-sections for morphological evaluation 
according to standard procedures. For immunofluorescence analysis, 8 µm-frozen 
sections were fixed in ice-cold acetone (10 minutes), air dried, and washed three times 
with Tris-buffered saline (TBS). After blocking with 10% goat serum in TBS, sections were 
stained with rat IgG2b anti-mouse CD45 monoclonal antibody, rat IgG2b anti-mouse 
F4/80 monoclonal antibody (1/100 dilution, Serotec, Martinsried/Planegg, Germany) or rat 
IgG2b anti-mouse CD11b monoclonal antibody (1/100 dilution, Serotec) followed by 
incubation with FITC-conjugated goat anti-rat IgG antibody (1/100 dilution, Santa Cruz, 
CA). Alternatively, to evaluate microvessel density, sections were incubated with rat 
IgG2a anti-mouse CD31 monoclonal antibody followed by incubation with biotinylated 
mouse anti-rat IgG1/2a antibody (both at 1/100 dilution, BD Pharmingen, San Diego, CA) 
and Texas red avidin (1/800 dilution, Vector Laboratories, Inc., Burlingame, CA). Nuclei 
were counterstained by 4’,6-diamidino-2-phenylindole (DAPI) (Sigma-Aldrich, Saint Louis, 
MO). For imaging analysis, CD31 immunostaining was performed on F4/80-prestained 
sections. Images were acquired using a Zeiss epifluorescence microscope (Zeiss Inc., 
North America) equipped with an Olympus N547 digital camera (Olympus, Hamburg, 
Germany) at x 200 magnification.  
 
Imaging and statistical analysis. Experimental groups include at least five mice. The 
Matrigel regions containing the most intense CD31+ areas of neovascularization 
(‘‘hotspots’’) were chosen for quantification. Five hotspots per Matrigel section and two 
sections per Matrigel plug were analyzed. The ImagePro Plus analysis system was used 
to measure CD31+ and F4/80+ areas in each hotspot. Statistical analysis was performed 
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with 2-tailed Student’s t-test. Differences were considered statistically significant at 
p<0.05. 
 
Chicken embryo chorioallantoic membrane (CAM) assay. Alginate beads (5 µL) 
containing vehicle or samples under test were prepared as described28 and placed on top 
of the CAM of fertilized White Leghorn chicken eggs at day 11 of incubation. After 72 
hours, blood microvessels entering the implants within the focal plane of the CAM were 
counted in ovo at x 5 magnification using a STEMI SR stereomicroscope equipped with 
an objective f equal to 100 mm with adapter ring 475070 (Zeiss). Then, the CAMs were 
cut, fixed with 4% paraformaldehyde, and stained May Grünwald-Giemsa to visualize the 
inflammatory infiltrate. The experiments were repeated at least twice. 
 
RESULTS 
 
Transcriptional profiling of FGF2-stimulated murine microvascular endothelial cells 
reveals a pro-inflammatory signature  
To assess the effect of FGF2 on the transcriptional profile of microvascular endothelium, 
confluent monolayers of mouse lung capillary endothelial 1G11 cells24 were stimulated for 
10 hours with 30 ng/mL FGF2 in low-serum culture medium. The transcriptional profile 
was then determined by microarray analysis using Affymetrix MOE4303A genechips 
(consisting of 22,690 probe sets, corresponding to approximately 15,000 genes) and 
compared to that of unstimulated cells. 
FGF2 treatment exerts a significant impact on the microvascular endothelial cell 
transcriptome. Indeed, 224 FGF2-modulated genes were identified after statistical 
analysis combined with 2-fold change filtering. Among these genes, 137 transcripts were 
upregulated following FGF2 stimulation whereas 84 genes were downregulated. Most of 
the FGF2-modulated transcripts correspond to annotated genes whereas 15 genes were 
unidentified or hypothetical (a comprehensive list of all the differentially expressed genes 
is provided in Supplementary Table 2).  
To gather biological information about the FGF2-regulated transcriptional profile, we 
performed data mining on the web-based Database for Annotation, Visualization and 
Integrated Discovery that provides functional genomic annotations according to Gene 
Ontology (GO) and other biological databases. The majority of FGF2-regulated genes fall 
in the functional categories of extracellular growth factors and cytokines, membrane 
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receptors, and transcription-related genes. Other major categories include signal 
transduction molecules, proteases and inhibitors, extracellular matrix components, cell 
adhesion molecules, membrane solute transporters, and enzymes. 
The most over-represented GO terms, based on their statistical significance, were 
“extracellular space” (cellular component), “receptor binding/growth factor activity” 
(molecular function), and “blood vessel morphogenesis/angiogenesis” (biological process) 
(Table 1). Accordingly, data mining on PubMed resources revealed a clear trend towards 
the process of new blood vessel formation. Indeed, several FGF2-upregulated genes 
encode for angiogenesis-promoting extracellular factors and cytokines, including FGF2 
itself, heparin-binding EGF-like growth factor (Hb-egf), prolactin family 2, subfamily c, 
member 2/Proliferin (Prl2c2/Plf), slit homolog-2 (Slit2), transforming growth factor (TGF) 
β1 and α, ephrin-B2 (EfnB2), Drm/gremlin-1, Ccl2, Cx3cl1, Cxcl16, platelet-derived 
growth factor-β (PdgfF-β), IL-6, and connective tissue growth factor (Ctgf). Angiogenesis-
related genes were also found in the categories of membrane receptors [anthrax toxin 
receptor-2 (Antxr2), calcitonin receptor-like receptor (Calcrl), integrin alpha 5 (Itg5), 
endothelial differentiation sphingolipid G-protein-coupled receptor-1 (Edg1), prostaglandin 
E receptor 4 (Ptger4), urokinase-type plasminogen activator receptor (Plaur), coagulation 
factor III (F3)], transcriptional regulators [(early growth response 1 (Egr1), runt related 
transcription factor (Runx) 1 and 2, ankyrin repeat domain 1 (Ankrd1)], cell adhesion 
molecules [CD44 antigen], proteases and their inhibitors [matrix metallopeptidase 13 
(Mmp13), serpine1] (Table 2). 
A second enriched biological category within the FGF2-modulated gene list was related to 
the bone formation process (GO terms “ossification”, “bone mineralization”, “regulation of 
bone remodelling”) (Table 1), a process in which FGF2 has been shown to play a relevant 
role29,30. Genes of this functional cluster include master regulators of osteoblast 
development and function as Tgfb1 and the transcriptional factor Runx2. Other genes 
related to bone remodelling were the prostaglandin receptor Ptger4, the transcriptional 
factor Egr2, the protease Mmp13, and downstream TGF-β1/Runx2 target genes like the 
bone matrix components Opn and Mgp (Table 2).  
Interestingly, a third prominent group of FGF2-induced genes was related to the 
inflammatory response (Table 1). As shown in Table 2, FGF2 upregulates the expression 
of a number of chemokines involved in the recruitment of different inflammatory cells such 
as monocytes/macrophages (Ccl2, Ccl7, Cx3cl1, Opn), neutrophils (Cxcl1), NK cells 
(Cx3cl1) and T lymphocytes (Cxcl16, Cx3cl1). Also, FGF2-induced genes include 
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inflammatory cytokines [IL-6, leukemia inhibitory factor (Lif), Opn] and cytokine receptors  
[oncostatin M receptor (Osmr), tumor necrosis factor receptor superfamily member 12a 
(Tnfrsf12a)/Tweak-receptor, interleukin 1 receptor accessory protein (IL1rap)], cell 
adhesion molecules related to leukocyte recruitment and transendothelial migration 
[vascular cell adhesion molecule 1 (Vcam1), junctional adhesion molecule 2 (JAM2)], as 
well as key inflammatory mediators like the cyclooxigenase Cox-2 and the prostaglandin 
E2 receptor Ptger4. 
It must be pointed out that, given the tight interplay among angiogenesis, bone formation, 
and inflammation, the role exerted by various genes mentioned above (eg Opn) is not 
limited to a single biological process (Table 2). 
 
Real-time PCR analysis of FGF2 upregulated genes  
Real-time quantitative PCR (qRT-PCR) was used to confirm the up-regulation of a 
number of selected inflammation-related genes (IL-6, Ccl2, Ccl7, Cx3cl1, Cxcl1, Cxcl16, 
Jam2, Ptgs2, Vcam1). To this aim, we analyzed the kinetics of expression of the selected 
genes in endothelial 1G11 cells from 0 to 24 hours after FGF2 stimulation. Data were 
normalized to actin-β expression which, according to our microarray results, behaves as a 
housekeeping gene.  
As shown in Figure 1, qRT-PCR analysis confirmed the upregulation of all the genes 
examined. Interestingly, FGF2 promotes an early upregulation (1 hour after treatment) for 
most of the inflammation-related genes examined (Ccl2, Ccl7, Cxcl1, Egr1, Ptgs2, and IL-
6), thus indicating that the induction of a pro-inflammatory signature represents an early 
event in FGF2-driven endothelial cell activation.  
 
FGF2 induces inflammatory cell recruitment in neovascularized areas  
The above results led us to investigate the presence of FGF2-triggered inflammatory cues 
in two different in vivo models of angiogenesis, the chick embryo CAM assay and the 
murine Matrigel plug assay.  
As shown in Figure 2, an alginate pellet containing FGF2 triggered a potent angiogenic 
response when applied on the top of the chick embryo CAM. Histological analysis of the 
FGF2-treated CAMs revealed the presence of a cell infiltrate in the stroma among the 
newly formed blood vessels. May Grünwald-Giemsa staining of paraffin-embedded 
sections confirmed the presence of inflammatory cells in the areas of CAM 
neovascularization (Figure 2). However, the lack of specific antibodies and the early stage 
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of development of the chick embryos did not allow a characterization of the inflammatory 
cells infiltrating the CAM. Next, the anti-inflammatory drugs hydrocortisone and 
ketoprofen were used to assess the overall impact of the inflammatory response on 
FGF2-induced angiogenesis in the CAM assay. As shown in Figure 2, both drugs were 
able to inhibit the angiogenic response triggered by FGF2, thus implicating inflammatory 
cells/mediators in FGF2-dependent neovascularization.   
In a second set of experiments, FGF2-embedded Matrigel plugs were implanted 
subcutaneously in mice and examined hystologically at day 7 after implantation (Figure 
3). Haematoxylin/eosin staining revealed the presence of numerous blood vessels and of 
an abundant cellular infiltrate in FGF2-embedded pellets, both absent in PBS-embedded 
control implants. Immunofluorescence analysis confirmed the presence of a potent 
neovascular response in FGF2-embedded plugs, as shown by the presence of numerous 
CD31+ endothelial cells, which was accompanied by a consistent CD45+ leukocyte 
infiltrate. The characterization of the leukocyte subsets revealed that the inflammatory cell 
infiltrate consists mainly of CD11b+ monocytes and F4/80+ macrophages (Figure 3). Only 
rare Gr-1+ neutrophils and CD8+ or CD4+ T-lymphocytes and no CD19+ B-lymphocytes, 
NK1.1+ natural killer, or CD11c+ dendritic cells were instead detectable (data not shown). 
These observations were confirmed for the same leukocyte subset markers by RT-PCR 
analysis of the total RNA extracted by the Matrigel plugs (D. Leali, unpublished 
observations). A time-course analysis of the cellular populations infiltrating the FGF2-
embedded Matrigel plugs revealed that monocytes/macrophages are already detectable 
within the plug at day 2 after implantation whereas a significant CD31+ neovascular 
response becomes evident on day 4 (data not shown). Thus, macrophage recruitment 
precedes neovascularization in FGF2-driven angiogenesis. 
  
Impairment of macrophage recruitment reduces FGF2-induced angiogenesis  
The above observations support the notion that inflammatory cells are relevant to FGF2-
dependent neovascularization. To further investigate this hypothesis, we evaluated the 
capacity of FGF2 to trigger an angiogenic response in the Matrigel plug assay under 
conditions that impair the recruitment of inflammatory cells. 
Proper migration of leukocyes to chemotactic agonists in inflammatory sites is dependent 
on PI3Kγ activity27,31. To investigate the potential role of infiltrating inflammatory cells in 
the modulation of FGF2-dependent angiogenesis, FGF2-embedded Matrigel plugs were 
implanted subcutaneously in PI3Kγ-/- mice and immunostaining of the plugs was 
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performed at day 7 after implantation. Computerized image analysis of the 
immunofluorescence signals demonstrated a significant reduction of the F4/80+ cell 
infiltrate (-60%) and, importantly, of CD31+ neovessels (-40%) in PI3Kγ-/- mice when 
compared to wild type control animals (Figure 4).  
In a second set of experiments, FGF2-induced angiogenesis was evaluated after 
macrophage depletion following intraperitoneal pretreatment with clodronate liposomes 
(Clodro-lip)32,33. Again, immunofluorescence analysis demonstrated a 72% reduction of 
the F4/80+ macrophage infiltrate and a 40% decrease of the CD31+ areas of 
neovascularization in FGF2-embedded Matrigel plugs implanted in Clodro-lip-treated 
animals when compared to animals injected with PBS-containing liposomes (PBS-lip) 
(Figure 4). Taken together, these results point to a role for pro-inflammatory macrophages 
in FGF2-induced angiogenesis in vivo. 
 
The conditioned medium from FGF2-stimulated microvascular cells is chemotactic 
for monocytes and promotes chemokine-dependent angiogenesis in vivo  
Microarray and qRT-PCR analysis of the transcriptional profile of FGF2-stimulated 
microvascular endothelial cells indicate that FGF2 upregulates the production of various 
chemokines that may serve to recruit monocytes in the neovascularized areas. To test 
this hypothesis, we evaluated the ability of the conditioned medium (CM) from FGF2-
stimulated microvascular 1G11 cells to induce monocyte chemotaxis in vitro. To avoid the 
possibility that exogenously added FGF2 may interfere with the biological activity of the 
CM from FGF2-treated cells, 1G11 cells were seeded on human recombinant FGF2 
immobilized to the substratum following its adsorption to plastic dishes26. Previous 
observations had shown that immobilized FGF2 retains a full biological activity, inducing 
receptor engagement, intracellular signalling, cell motility, and cell proliferation34. 
Following a 24 hour-stimulation by immobilized FGF2, cells extracts and CM were 
analyzed for gene expression and monocyte chemotactic activity, respectively. Under 
these experimental conditions, the concentration of human FGF2 in the CM was typically 
lower than 1.0 ng/mL, as assessed by ELISA. As controls, 1G11 cells cultured for 24 
hours on non-coated dishes or stimulated with soluble FGF2 (30 ng/mL) were analyzed in 
parallel. As shown in Supplementary Figure 1, both immobilized and free FGF2 induced 
the upregulation of selected chemotactic factors, thus confirming the ability of substratum-
bound FGF2 to activate endothelial cells. 
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Next, the CM from control and FGF2-stimulated 1G11 cells were tested in a Boyden 
chamber assay for the capacity to induce a chemotactic response in freshly isolated 
monocytes from healthy blood donors. As shown in Figure 5A, the CM from FGF2-
stimulated 1G11 cells exerted a dose-dependent chemotactic response in human 
monocytes whereas the CM from control cells was ineffective. Importantly, the 
chemotactic response of human monocytes was inhibited in a dose-dependent manner 
when the CM from FGF2-stimulated 1G11 cells was pre-incubated with the pan-
chemokine inhibitor M3 (Figure 5B), a murine gammaherpesvirus 68 protein that binds 
with high affinity to human and mouse CC, CXC and CX3C chemokines35. Taken 
together, these observations indicate that FGF2-activated endothelium expresses and 
secretes biologically active chemokine(s) that represent a chemotactic stimulus for human 
monocytes. 
On this basis, the CM from FGF2-stimulated microvascular 1G11 cells was investigated 
for the capacity to induce neovascularization in vivo in the chick embryo CAM assay. As 
shown in Figure 6A, the CM from FGF2-stimulated endothelial cells exerted a potent 
angiogenic response that was significantly reduced in the presence of the pan-chemokine 
inhibitor M3. Accordingly, the intense cellular infiltrate observed in the areas of 
neovascularization induced by the CM from FGF2-stimulated cells was almost abolished 
in the presence of M3 (Figure 6B). These observations support the notion that the CM 
from FGF2-activated microvascular endothelium promotes a chemokine-dependent 
angiogenic response. In keeping with these observations, the pan-chemokine inhibitor M3 
induced a significant inhibitory effect on neovascularization induced by recombinant 
FGF2, without affecting the basal levels of vascularization of the CAM (Figure 7). Taken 
together, these findings demonstrate a relevant role for pro-inflammatory chemokines in 
FGF2-driven angiogenesis. 
 
DISCUSSION  
In the present study, we provide evidence that FGF2 promotes pro-inflammatory signals in 
microvascular endothelial cells and that FGF2-induced chemokines and infiltrating 
monocytes/macrophages are important mediators of the neovascularization process 
elicited by the growth factor.  
Gene expression profiling and qRT-PCR experiments demonstrated that FGF2 upregulates 
the expression of several endothelial genes encoding for proteins tightly related to the 
inflammatory response, including cell adhesion molecules, members of the 
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eicosanoid/cyclooxigenase pathway, and various cytokines/chemokines and their 
receptors. Accordingly, the CM from FGF2-stimulated microvascular endothelial cells 
exerted a chemotactic activity for human monocytes and elicited a potent angiogenic 
response when delivered on the top of the chick embryo CAM. Importantly, both effects 
were inhibited by the pan-chemokine inhibitor M3. Consistent with these findings, the 
angiogenic response elicited in vivo by recombinant human FGF2 in the CAM assay is 
accompanied by the appearance of an inflammatory infiltrate in the areas of 
neovascularization. Also, the characterization of the FGF2-induced inflammatory infiltrate, 
performed in the murine Matrigel plug assay, demonstrated that recruited CD45+ 
leukocytes consist mainly of CD11b+ and of F4/80+ mononuclear cells.  
Importantly, FGF2-triggered angiogenesis was significantly reduced in the CAM assay by 
mechanistically distinct steroidal (hydrocortisone) and non-steroidal (ketoprofen) anti-
inflammatory drugs and by the viral pan-chemokine inhibitor M3. Also, the decreased 
angiogenic response elicited in the murine Matrigel plug assay by human recombinant 
FGF2 in PI3Kγ-/- mice exhibiting defective leukocyte migration or following macrophage 
depletion by clodronate liposome pre-treatment points to a functional involvement of 
infiltrating monocytes/macrophages in FGF2-driven angiogenesis.  
It is well known that monocytes/macrophages are active players in pathological 
angiogenesis, including tumor neovascularization36-39. Monocytes/macrophages can 
produce pro-angiogenic growth factors (e.g. VEGF, FGF2, IL-1β, IL-8, TNF-α) and 
proteases known to support angiogenesis by remodeling the extracellular matrix40,41. 
Monocytes/macrophages are frequently associated with proliferating blood vessels42 and 
can open passages in existing vasculature to facilitate the development of vascular 
sprouts41. Thus, monocytes/macrophages often precede, temporally and spatially, the 
formation of new vascular sprouts, altering the microenvironment and promoting 
subsequent endothelial cell migration, proliferation, and vessel formation. Accordingly, we 
have observed that the recruitment of mononuclear phagocytes precedes blood vessel 
formation in FGF2-driven angiogenesis in the Matrigel plug assay.  
Interestingly, various observations argue for the ability of monocytes to contribute to new 
blood vessel formation by differentiating in endothelial-like cells43,44. Moreover, recent 
observations have shown that PI3Kγ knockout impairs endothelial cell precursor functions 
and integration in endothelial cell networks45. To this respect, the capacity of 
monocytes/macrophages to cooperate with endothelial cell precursors during FGF2-
driven neovascularization in a long-term (4 weeks) Matrigel plug assay has been recently 
 15
suggested46. Also in this case, numerous F4/80+ cells surrounding the microvessels were 
observed within the plug. In this long-term study, monocytes/macrophages appear to 
contribute to extracellular matrix degradation, facilitating the invasion of Tie2+ precursors 
and blood vessel lumen formation. Here, we extend these observations by demonstrating 
a functional, non-redundant early role for monocytes/macrophages in FGF2-driven 
angiogenesis. 
Consistent with their pro-angiogenic role, the depletion of monocytes/macrophages 
reduces neovascularization driven by VEGF47,48, PIGF49, and IL-1β50. Thus, 
monocytes/macrophages appear to play a non-redundant role in the angiogenesis 
process driven by various angiogenic growth factors, including FGF2, thus confirming the 
tight correlation between inflammatory and angiogenic responses. 
In addition to monocytes/macrophages, other inflammatory cells, like polymorphonuclear 
neutrophils and mast cells, may contribute to pathological angiogenesis40,51,52. To this 
respect, corneal neovascularization in response to FGF2 is diminished in neutropenic mice 
53, thus indicating that different inflammatory cells may sustain FGF2-induced 
angiogenesis. Further studies are required to elucidate the possible cross-talk between 
polymorphonuclear neutrophils and monocytes/macrophages in mediating the activity of 
angiogenic growth factors, including FGF2. 
Our observations indicate that FGF2-driven angiogenesis is, at least in part, chemokine-
dependent. It is tempting to speculate that chemotactic factors produced by FGF2-
stimulated endothelium may recruit mononuclear phagocytes that, in turn, will amplify the 
angiogenic response by releasing monocyte-derived pro-angiogenic cytokines. For 
instance, Opn, a cytokine endowed with a potent chemoattractant activity for monocytes, is 
strongly induced by FGF2 in endothelial cells (present work and12). In turn, Opn induces 
neovascularization12 by recruiting monocytes/macrophages and promoting the release the 
pro-angiogenic cytokine IL-1β11. Also, FGF2-induced chemoattractants may play a direct 
role in neovascularization. Indeed, various chemokines have been shown to function as 
angiogenic factors by a direct interaction with specific chemokine receptors expressed on 
endothelial cells, thus promoting proliferation, migration, and capillary tube formation9,54. 
Among them, the FGF2-induced chemokines Ccl2, Cxcl1, Cxcl16 and Cxc3l1 could act as 
enhancers of the neovascularization process elicited by the growth factor.  
The capacity of the pan-chemokine inhibitor M3 to inhibit angiogenesis triggered by FGF2 
or by the CM from FGF-2 stimulated endothelial cells is of interest. M3, a secreted 44 kDa 
protein encoded by murine gammaherpesvirus 68 (MHV-68), binds with high affinity to a 
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broad range of murine and human chemokines of the CC, CXC, CX3C, and C families, 
precluding their interaction with cognate chemokine receptors35. Accordingly, M3 prevents 
chemokine-mediated signal transduction and chemotaxis and blocks leukocyte recruitment 
induced by a number of chemokines including Ccl2155, Ccl2, and Cxcl1356. At the light of 
our findings, M3 protein may represent the basis for the design of novel angiogenesis 
inhibitors with therapeutic implications in a variety of angiogenesis-dependent pathological 
conditions, including tumor growth and metastasis. 
Taken together, our findings support the notion that monocytes/macrophages and 
inflammation-related gene products actively participate in the angiogenic process elicited 
by FGF2 as part of a complex cascade of cellular and molecular events triggered by the 
growth factor on microvascular endothelium. Indeed, we have shown that FGF2 
upregulates also the expression of a variety of angiogenic growth factors in endothelial 
cells, including FGF2 itself. This indicates that FGF2 is able to activate an autocrine loop of 
amplification of the angiogenic response that, together with the paracrine activity exerted by 
endothelium-derived cytokines/chemokines on inflammatory cells, will contribute to the 
modulation of the neovascularization process triggered by the growth factor. 
FGF2 expression is augmented at sites of chronic inflammation in rheumatoid arthritis18, 
inflammatory bowel disease17, asthma57, after tissue injury58, and in different types of 
human cancer15. FGF2 lacks a conventional signal peptide and its release may occur 
through alternative pathways of secretion59,60. Also, FGF2 is released following cell death, 
wounding or sublethal injury61-63. Moreover, inflammatory mediators, including interferon-α 
plus IL-264, IL-1β 65, and nitric oxide66, can activate the endothelium to synthesize and 
release FGF2. Our observations suggest that FGF2 released after tissue damage may 
contribute to the host defense responses by activating pro-angiogenic and pro-
inflammatory signatures in endothelium that, by acting in concert, will lead to neovessel 
formation and monocyte/macrophage engagement. Relevant to this point, Fgf2-null mice 
exhibit delayed wound repair67 and local application of FGF2 effectively improves wound 
repair68-70, the healing process being accompanied by mononuclear cell infiltrate 
recruitment71. On the other hand, long-term stimulation by FGF2 down-modulates 
monocyte transendothelial migration in vitro and the expression of cell adhesion molecules 
in human umbilical vein endothelial cells72. Similarly, monocyte/macrophages adhesion to 
endothelium and the chemotactic response to various chemokines are inhibited by long-
term stimulation by FGF273, suggesting that the pro- or anti-inflammatory activity of FGF2 
may be contextual (discussed in15).   
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In conclusion, our findings point to inflammatory chemokines as important early mediators 
of FGF2-driven angiogenesis and indicate a relevant role for inflammatory cells in the 
neovascularization process elicited by the growth factor. Conversely, FGF2 may exert 
important functions at sites of inflammation and/or tissue injury not only by inducing 
neovascularization but also by contributing to the activation of innate immune responses. 
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 FGF2-upregulated genes were classified in terms of their associated GO biological 
processes, cellular components and molecular functions. The most over-represented GO 
terms, the number and percentage of genes belonging to each category, and the 
statistical significance are shown. 
Table 1. Over-represented GO terms for FGF2-upregulated genes 
GO Term Genes % Significance 
Biological process    
Blood vessel morphogenesis 19 6,8 2,2E-09 
Angiogenesis 16 5,7 4,5E-08 
Ossification 13 4,6 2,0E-07 
Bone mineralization 8 2,9 3,8E-05 
Regulation of bone remodeling 7 2,5 2,7E-05 
Inflammatory response 12 4,3 4,4E-04 
Molecular function    
Receptor binding 34 12,1 1,0E-07 
Growth factor activity 18 6,4 1,1E-07 
Cytokine activity 19 6,8 2,5E-06 
Cellular component    
Extracellular space 69 24,6 2,5E-04 
Extracellular region 71 25,4 5,8E-04 
Basolateral plasma membrane 6 2,1 6,0E-03 
Extracellular matrix 10 3,6 5,2E-02 
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Table 2. FGF2-upregulated genes in murine microvascular 1G11 endothelial cells 
related to angiogenesis, bone remodelling, and inflammation. 
Growth factors, cytokines and chemokines Symbol Biological Process Fold change Unigene ID 
chemokine (C-C motif) ligand 2 Ccl2 A/I 3.5 Mm.290320 
chemokine (C-C motif) ligand 7 Ccl7 I 3.1 Mm.341574 
chemokine (C-X3-C motif) ligand 1 Cx3cl1 A/I 2.0 Mm.103711 
chemokine (C-X-C motif) ligand 1 Cxcl1 A/I 1.7 Mm.21013 
chemokine (C-X-C motif) ligand 16 Cxcl16 A/I 2.0 Mm.301293 
connective tissue growth factor Ctgf A/B 2.3 Mm.393058 
ephrin B2 Efnb2 A/B 2.1 Mm.209813 
fibroblast growth factor 2 Fgf2 A/B/I 2.3 Mm.457975 
gremlin 1 Grem1 A 3.1 Mm.458492 
heparin-binding EGF-like growth factor Hbegf A 8.4 Mm.289681 
interleukin 6 Il6 A/B/I 3.8 Mm.1019 
leukemia inhibitory factor Lif B/I 2.3 Mm.4964 
platelet derived growth factor, B polypeptide Pdgfb A 3.2 Mm.144089 
prolactin family 2, subfamily c, member 2/Proliferin Prl2c2/Pfl  A 13.5 Mm.88796 
secreted phosphoprotein 1/osteopontin Spp1/Opn A/B/I 12.2 Mm.288474 
slit homolog 2 (Drosophila) Slit2 A/I 3.0 Mm.289739 
thrombospondin 1 Thbs1 A/B/I 2.7 Mm.4159 
transforming growth factor alpha Tgfa A 2.2 Mm.137222 
transforming growth factor, beta 1 Tgfb1 A/B/I 2.2 Mm.248380 
tumor necrosis factor, alpha-induced protein 2 Tnfaip2 A 2.3 Mm.255332 
Membrane receptors and adhesion molecules Symbol Biological Process Fold change Unigene ID 
anthrax toxin receptor 2 Antxr2 A 2.7 Mm.24842 
calcitonin receptor-like Calcrl A/B 2.3 Mm.75467 
CD44 antigen Cd44 A/I 6.1 Mm.423621 
coagulation factor III F3/Tf A/I 2.9 Mm.273188 
endothelial differentiation sphingolipid G-protein-coupled 
receptor 1 
Edg1 A 4.1 Mm.982 
interleukin 1 receptor accessory protein Il1rap I 2.3 Mm.253424 
junction adhesion molecule 2 Jam2 I 2.3 Mm.41758 
oncostatin M receptor Osmr A/B/I 2.2 Mm.10760 
plasminogen activator, urokinase receptor Plaur A/B/I 3.2 Mm.1359 
prostaglandin E receptor 4 (subtype EP4) Ptger4 A/B/I 4.9 Mm.18509 
tumor necrosis factor receptor superfamily, member 12a Tnfrsf12a A/B/I 2.9 Mm.28518 
vascular cell adhesion molecule 1 Vcam1 I 3.1 Mm.76649 
Transcriptional regulators Symbol Biological Process Fold change Unigene ID 
early growth response 1 Egr1 A 3.4 Mm.181959 
early growth response 2 Egr2 B 5.6 Mm.290421 
runt related transcription factor 1 Runx1 A/B 2.8 Mm.4081 
runt related transcription factor 2 Runx2 A/B 2.1 Mm.391013 
ankyrin repeat domain 1 (cardiac muscle) Ankrd1 A 3.6 Mm.10279 
Others Symbol Biological Process Fold change Unigene ID 
integrin alpha 5 (fibronectin receptor alpha) Itga5 A 2.0 Mm.16234 
matrix Gla protein Mgp B 4.1 Mm.243085 
matrix metallopeptidase 13 Mmp13 A/B 22.1 Mm.5022 
prostaglandin-endoperoxide synthase 2 Ptgs2 A/B/I 18.5 Mm.292547 
serine (or cysteine) peptidase inhibitor, clade E, member 1 Serpine1 A/I 3.0 Mm.250422 
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FGF2-upregulated genes (p< 0.05, FDR=5%, fold change > 2) were classified in terms of 
their association with angiogenesis (A), bone formation (B), and inflammation (I) 
processes, according to the GO and Pubmed databases. The official gene name and 
symbol, the fold change increase and the Unigene cluster number are shown. 
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LEGENDS TO FIGURES 
 
Figure 1. qRT-PCR time course analysis of selected inflammation-related genes in 
FGF2-stimulated endothelial cells. Serum starved 1G11 endothelial cells were 
stimulated with 30 ng/mL of FGF2 for 0, 1, 2, 4, 8, 12 and 24 hours. Total RNA from each 
time point was reverse transcribed to cDNA and analysed by real time PCR. Data (mean 
values ± SD, n=3) represent the expression ratio of each target gene relative to the 
untreated control. Expression levels were normalized to β-actin gene.  
 
Figure 2. FGF2 induces angiogenic and inflammatory responses in the chick 
embryo CAM assay. A) Alginate beads containing vehicle (PBS) or 150 ng of FGF2 
(FGF2) were implanted on top of chick embryo CAMs at day 11 of development. After 3 
days, CAMs were assessed for new vessel formation (upper panels) using a 
stereomicroscope (original magnification, x 5) and for inflammatory cell infiltration (lower 
panles) by May Grünwald-Giemsa staining of paraffin-embedded sections (Original 
magnification, x 40). Note the strong presence of inflammatory cells (arrowheads) in the 
areas of FGF2-induced neovascularization, as shown in the enlarged lower right panel. 
Alginate implant (AI), vessel (v). B) Alginate implants containing vehicle or 150 ng of 
FGF2 were assessed for their angiogenic capacity  in the absence or presence of 50 µg 
of hydrocortisone or 50 µg of ketoprofen. Data (10 eggs per group) represent the number 
of vessels converging towards the alginate implant and are expressed as mean ± SD.  
 
Figure 3. Inflammatory cell infiltrate the areas of FGF2-induced neovascularization 
in Matrigel plugs. Matrigel pellets containing PBS or 150 ng of FGF2 were implanted 
subcutaneously in mice and examined at day 7 by haematoxylin/eosin (H&E) staining and 
immunofluorescence analysis with antibodies specific to the indicated antigens. Note the 
presence in the implanted FGF2-Matrigel plugs of numerous CD31+ endothelial cells and 
of CD45+ infiltrating leukocytes, mainly consisting of CD11b+ monocytes and F4/80+ 
macrophages. Nuclei are shown by DAPI counterstaining. Original magnification, x 200. 
 
Figure 4. Defective macrophage recruitment impairs FGF2-induced angiogenesis. 
A) Immunohistochemical analysis of FGF2-Matrigel pellets from wild type (wt) or PI3Kγ-/- 
SV129 mice and from C57Bl/6 mice that received PBS-Lips or clodro-Lips i.p. Matrigel 
sections were double-stained with anti-CD31 (red) and anti-F4/80 (green) monoclonal 
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antibodies. Original magnification, x 200. B) Quantitative analysis of infiltrating CD31+ 
endothelial cells and F4/80+ macrophages in FGF2-Matrigel plugs on day 7 after 
implantation. Data (mean ± SD) represent the percentage of CD31+ (red bars) or F4/80+ 
(green bars) immunopositive areas of Matrigel sections from PI3Kγ-/- or Clodro-Lip-
treated mice relative to their respective wt and PBS-lip-treated controls. *p< 0.05. 
  
Figure 5. The conditioned medium from FGF2-stimulated microvascular endothelial 
cells is chemotactic to monocytes. A) The migration of human monocytes towards 
different dilutions of the conditioned medium from non stimulated (Control_CM) and 
FGF2-stimulated (FGF2_CM) 1G11 endothelial cells was quantified as described in 
Materials and Methods. Data are expressed as the mean number of migrated cells per 
field. B) Inhibition of the chemotactic response of 1G11 endothelial cells towards FGF2-
conditioned medium by different concentrations of the pan-chemokine inhibitor M3. 
Chemotaxis was tested at the dose of FGF2_CM that induced maximal chemotactic 
responses (1/300 dilution) and compared to the equivalent dilution of Control_CM. Data 
are expressed as the number of migrated cells per field. 
 
Figure 6. The conditioned medium from FGF2-stimulated microvascular endothelial 
cells promotes chemokine-dependent angiogenesis in vivo. A) Chick embryo CAM 
assay was performed with the conditioned medium from non-stimulated (Control_CM) 
and FGF2-stimulated (FGF2_CM) 1G11 endothelial cells in the absence or presence of 
75 ng of the pan-chemokine inhibitor M3. Data are expressed as the mean ± SD of the 
number of vessels invading the alginate area. B) Representative histological sections of 
CAMs from the different experimental groups (May Grünwald-Giemsa staining). Note that 
FGF2_CM induces neovascularization and a strong inflammatory cell infiltrate within the 
alginate implant (AI), both greatly reduced in the presence of M3. 
 
Figure 7. Pan-chemokine inhibitor M3 impairs FGF2-induced angiogenesis. CAMs 
were implanted at day 11 of development with alginate beads containing vehicle (PBS), 
150 ng of FGF2, 75 ng of M3, or 150 ng of FGF2 added with 75 ng of M3. After 3 days, 
CAMs were photographed (A, original magnification x 5) and angiogenesis was quantified 
by counting the number of microvessels (mean ± SD ) invading the alginate area (B). 
Note the significant reduction in the number of newly-formed microvessels converging 
towards the FGF2 implant in the presence of the M3 inhibitor. 
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Supplementary Table 1. Oligonucleotide primer sequences for real time qPCR. 
 
Gene  RefSeq  Forward Reverse Amplicon  
Actb NM_007393  CGTAAAGACCTCTATGCCAACA CCACCGATCCACACAGAGA 161 
Ccl2 NM_011333 CTTCTGGGCCTGCTGTTCA CCAGCCTACTCATTGGGATCA 127 
Ccl7 NM_013654 CCTGGGAAGCTGTTATCTTCA TTGGCTCCTAGGTTGGTTTC 159 
Cx3cl1 NM_009142 CATGTGCGACAAGATGACC CTTGGACCCATTTCTCCTTC 149 
Cxcl16 NM_023158 CCATTCTTTATCAGGTTCCAGT CTCGTGTCCGAAGGTGTC 200 
Egr1 NM_007913  CCTGACCACAGAGTCCTTTT ATAGGTGATGGGAGGCAAC 103 
IL6 NM_031168 GAGGATACCACTCCCAACAGACC AAGTGCATCATCGTTGTTCATACA 141 
Jam2 NM_023844 TGCTGGAGAGTATCGCTGT CTTCTTTATCCTGGCATCGT 157 
Ptgs2 NM_011198   GGTGTGAACAATCAAACAAAATG TAACATGCTTGGGTCAGTCAAT 160 
Vcam1 NM_011693 GAACTGATTATCCAAGTCTCTCCA CCATGTCTCCTGTCTTTGCTT 157 
 
Supplementary Table 2. FGF2-regulated genes in microvascular endothelial cells. 
 
FGF2-upregulated genes (fold change ≥ 2, P < 0.05) 
UniGene ID Gene Title Gene Symbol Fold change 
Mm.5022 matrix metallopeptidase 13 Mmp13 22.1 
Mm.292547 prostaglandin-endoperoxide synthase 2 Ptgs2 18.5 
Mm.331191 small proline-rich protein 1A Sprr1a 16.5 
Mm.88796 prolactin family 2, subfamily c, member 2* Prl2c2 /// Prl2c3 
/// Prl2c4 
13.5 
Mm.288474 secreted phosphoprotein 1 Spp1 12.2 
Mm.289681 heparin-binding EGF-like growth factor Hbegf 8.4 
Mm.4791 epiregulin Ereg 8.1 
Mm.28405 serum/glucocorticoid regulated kinase Sgk 8.0 
Mm.157190 high mobility group AT-hook 2 Hmga2 7.7 
Mm.263002 protein kinase, cGMP-dependent, type II Prkg2 7.0 
Mm.318841 ERBB receptor feedback inhibitor 1 Errfi1 6.1 
Mm.29959 RIKEN cDNA 1600029D21 gene 1600029D21Rik 6.1 
Mm.423621 CD44 antigen Cd44 6.1 
Mm.25775 RIKEN cDNA 1810011O10 gene 1810011O10Rik 5.9 
Mm.271870 serine (or cysteine) peptidase inhibitor, clade B, member 2 Serpinb2 5.7 
Mm.290421 early growth response 2 Egr2 5.6 
Mm.207365 involucrin Ivl 5.0 
Mm.290780 tumor necrosis factor receptor superfamily, member 23 Tnfrsf23 4.9 
Mm.18509 prostaglandin E receptor 4 (subtype EP4) Ptger4 4.9 
Mm.6215 fos-like antigen 1 Fosl1 4.3 
Mm.261384 tumor necrosis factor receptor superfamily, member 22 Tnfrsf22 4.2 
Mm.243085 matrix Gla protein Mgp 4.2 
Mm.982 endothelial differentiation sphingolipid G-protein-coupled receptor 1 Edg1 4.1 
Mm.1019 interleukin 6 Il6 3.8 
Mm.4438 high mobility group AT-hook 1 Hmga1 3.8 
Mm.441810 Rho GTPase activating protein 6 Arhgap6 3.7 
Mm.227506 poliovirus receptor Pvr 3.7 
Mm.10279 ankyrin repeat domain 1 (cardiac muscle) Ankrd1 3.6 
Mm.399 immediate early response 2 Ier2 3.6 
Mm.153566 meteorin, glial cell differentiation regulator-like Metrnl 3.6 
Mm.24402 glutamine fructose-6-phosphate transaminase 2 Gfpt2 3.5 
Mm.290320 chemokine (C-C motif) ligand 2 Ccl2 3.5 
Mm.181959 early growth response 1 Egr1 3.4 
Mm.86541 CCR4 carbon catabolite repression 4-like (S. cerevisiae)  Ccrn4l 3.4 
Mm.2444 myelocytomatosis oncogene Myc 3.3 
Mm.294708 RIKEN cDNA A030007L17 gene A030007L17Rik 3.2 
Mm.1359 plasminogen activator, urokinase receptor Plaur 3.2 
Mm.21002 solute carrier family 2 (facilitated glucose transporter), member 1 Slc2a1 3.2 
Mm.255848 hexokinase 2 Hk2 3.2 
 1
Mm.1791 dual specificity phosphatase 6 Dusp6 3.2 
Mm.144089 platelet derived growth factor, B polypeptide Pdgfb 3.2 
Mm.10651 GTP cyclohydrolase 1 Gch1 3.1 
Mm.458492 gremlin 1 Grem1 3.1 
Mm.277518 monocyte to macrophage differentiation-associated  Mmd 3.1 
Mm.76649 vascular cell adhesion molecule 1 Vcam1 3.1 
Mm.341574 chemokine (C-C motif) ligand 7 Ccl7 3.1 
Mm.250422 serine (or cysteine) peptidase inhibitor, clade E, member 1 Serpine1 3.0 
Mm.258893 solute carrier family 4, sodium bicarbonate cotransporter, member 7 Slc4a7 3.0 
Mm.289739 slit homolog 2 (Drosophila) Slit2 3.0 
Mm.28262 regulator of G-protein signaling 2 Rgs2 3.0 
Mm.1167 Jun-B oncogene Junb 2.9 
Mm.28518 tumor necrosis factor receptor superfamily, member 12a Tnfrsf12a 2.9 
Mm.119 nuclear receptor subfamily 4, group A, member 1 Nr4a1 2.9 
Mm.286407 SRY-box containing gene 9 Sox9 2.9 
Mm.21288 elongation factor RNA polymerase II 2 Ell2 2.9 
Mm.273188 coagulation factor III F3 2.9 
Mm.168 interferon-related developmental regulator 1 Ifrd1 2.8 
Mm.4081 runt related transcription factor 1 Runx1 2.8 
Mm.24842 anthrax toxin receptor 2 Antxr2 2.7 
Mm.8039 amphiregulin Areg 2.7 
Mm.245210 leucine-rich repeats and immunoglobulin-like domains 1 Lrig1 2.7 
Mm.65021 N-myristoyltransferase 2 Nmt2 2.7 
Mm.4159 thrombospondin 1 Thbs1 2.7 
Mm.85429 six transmembrane epithelial antigen of the prostate 1 Steap1 2.6 
Mm.347919 cardiotrophin-like cytokine factor 1 Clcf1 2.6 
Mm.119320 carbonic anhydrase 8 Car8  2.6 
Mm.247470 troponin T2, cardiac Tnnt2 2.6 
Mm.36640 mitogen-activated protein kinase kinase kinase 6 Map3k6 2.6 
Mm.387108 ERO1-like (S. cerevisiae) Ero1l 2.6 
Mm.89940 a disintegrin and metallopeptidase domain 19 (meltrin beta)  Adam19 2.5 
Mm.8245 tissue inhibitor of metalloproteinase 1 Timp1 2.5 
Mm.1870 FXYD domain-containing ion transport regulator 5 Fxyd5 2.5 
Mm.13787 ceruloplasmin Cp 2.5 
Mm.18814 BAI1-associated protein 2-like 1 Baiap2l1 2.5 
Mm.27467 ras homolog gene family, member J Rhoj 2.5 
Mm.319581 cytoplasmic tyrosine kinase, Dscr28C related (Drosophila) Tec 2.5 
Mm.440795  RIKEN cDNA E430024C06 gene  similar to gag 
protein 
2.5 
Mm.396078 lymphatic vessel endothelial hyaluronan receptor 1 Lyve1 2.4 
Mm.323901 solute carrier family 20, member 2  Slc20a2 2.4 
Mm.248361 deafness, autosomal dominant 5 homolog (human) Dfna5h 2.4 
Mm.22650 serine (or cysteine) peptidase inhibitor, clade A, member 3N Serpina3n 2.4 
Mm.436548 testis derived transcript Tes 2.4 
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Mm.10222 WNT1 inducible signaling pathway protein 1 Wisp1 2.4 
Mm.293635 solute carrier family 25, member 37 Slc25a37 2.4 
Mm.75467 calcitonin receptor-like Calcrl 2.3 
Mm.332931 RIKEN cDNA 1200015M12 gene * 1200015M12Rik 2.3 
Mm.27740 tumor necrosis factor, alpha-induced protein 8 Tnfaip8 2.3 
Mm.41758 junction adhesion molecule 2 Jam2 2.3 
Mm.255332 tumor necrosis factor, alpha-induced protein 2 Tnfaip2 2.3 
Mm.3117 pleckstrin homology-like domain, family A, member 1 Phlda1 2.3 
Mm.4964 leukemia inhibitory factor Lif 2.3 
Mm.457975 fibroblast growth factor 2 Fgf2 2.3 
Mm.380 polo-like kinase 2 (Drosophila) Plk2 2.3 
Mm.253424 interleukin 1 receptor accessory protein Il1rap 2.3 
Mm.945 protein tyrosine phosphatase, receptor type, E Ptpre 2.3 
Mm.393058 connective tissue growth factor Ctgf 2.3 
Mm.246479 OAF homolog (Drosophila) Oaf 2.3 
Mm.12882 hydroxysteroid (17-beta) dehydrogenase 7 Hsd17b7 2.3 
Mm.399997 solute carrier family 12, member 2  Slc12a2 2.3 
Mm.103439 G protein-coupled receptor, family C, group 5, member B Gprc5b 2.3 
Mm.136604 nuclear factor, interleukin 3, regulated* Nfil3 2.3 
Mm.3863 P450 (cytochrome) oxidoreductase Por 2.2 
Mm.266679 tribbles homolog 2 (Drosophila) Trib2 2.2 
Mm.248380 transforming growth factor, beta 1 Tgfb1 2.2 
Mm.258908 Friend leukemia integration 1 Fli1 2.2 
Mm.5025 ets variant gene 4 (E1A enhancer binding protein, E1AF) Etv4 2.2 
Mm.259653 RAS p21 protein activator 1 Rasa1 2.2 
Mm.10760 oncostatin M receptor Osmr 2.2 
Mm.272183 B-cell translocation gene 1, anti-proliferative* Btg1 2.2 
Mm.212395 retinoic acid induced 14 Rai14 2.2 
Mm.137222 transforming growth factor alpha Tgfa 2.2 
Mm.360747 carbohydrate sulfotransferase 11 Chst11 2.2 
Mm.319847 leucine rich repeat containing 8 family, member C Lrrc8c 2.2 
Mm.274847 glutamate-rich WD repeat containing 1 Grwd1 2.1 
Mm.316652 3-hydroxy-3-methylglutaryl-Coenzyme A reductase Hmgcr 2.1 
Mm.246513 FBJ osteosarcoma oncogene Fos 2.1 
Mm.41171 tumor necrosis factor (ligand) superfamily, member 9 Tnfsf9 2.1 
Mm.241073 ectodermal-neural cortex 1 Enc1 2.1 
Mm.2093 snail homolog 1 (Drosophila) Snai1 2.1 
Mm.41288 membrane protein, palmitoylated 6 (MAGUK p55 subfamily member 6) Mpp6 2.1 
Mm.398181 UDP-Gal:betaGlcNAc beta 1,4-galactosyltransferase, polypeptide 6 B4galt6 2.1 
Mm.209813 ephrin B2 Efnb2 2.1 
Mm.391013 runt related transcription factor 2 Runx2 2.1 
Mm.392726 sprouty protein with EVH-1 domain 1, related sequence Spred1 2.1 
Mm.149403 cytochrome b-561 Cyb561 2.1 
 3
Mm.225505 choline kinase alpha Chka 2.1 
Mm.443 methylenetetrahydrofolate dehydrogenase (NAD+ dependent), 
methenyltetrahydrofolate cyclohydrolase 
Mthfd2 2.0 
Mm.86646 v-maf musculoaponeurotic fibrosarcoma oncogene family, protein F (avian) Maff 2.0 
Mm.390014 RAB20, member RAS oncogene family Rab20 2.0 
Mm.103711 chemokine (C-X3-C motif) ligand 1 Cx3cl1 2.0 
Mm.425467 solute carrier organic anion transporter family, member 3a1 Slco3a1 2.0 
Mm.457995 solute carrier family 20, member 1 Slc20a1 2.0 
Mm.5540 RIKEN cDNA 1810054D07 gene 1810054D07Rik 2.0 
Mm.273197 RIKEN cDNA 2010002N04 gene 2010002N04Rik 2.0 
Mm.16234 integrin alpha 5 (fibronectin receptor alpha) Itga5 2.0 
Mm.28095 filamin, beta Flnb 2.0 
Mm.301293 chemokine (C-X-C motif) ligand 16 Cxcl16 2.0 
Mm.442561 interferon activated gene 204 Ifi204 2.0 
Mm.4292 TGFB inducible early growth response 1 Tieg 2.0 
Mm.25613 immediate early response 3 Ier3 2.0 
Mm.114382 sprouty protein with EVH-1 domain 2, related sequence Spred2 2.0 
Mm.140158 cytochrome P450, family 51 Cyp51 2.0 
Mm.12246 immediate early response 5 Ier5 2.0 
Mm.210035 Early endosome antigen 1 Eea1 2.0 
Mm.29164 cell division cycle associated 7 Cdca 2.0 
Mm.32506 stanniocalcin 2 Stc2 2.0 
Mm.143689 fatty acid-Coenzyme A ligase, long chain 4 Facl4 2.0 
FGF2-downregulated genes (fold change ≤ 2, p< 0.05) 
UniGene ID Gene Title Gene Symbol Fold change 
Mm.440573 methyltransferase like 7A  Mettl7a 
-5,6
Mm.26838 aldo-keto reductase family 1, member C14 Akr1c14 
-5,0
Mm.378235 D site albumin promoter binding protein Dbp 
-4,3
Mm.440573 UbiE-YGHL1 fusion protein Ubie 
-4,2
Mm.371580 sorbitol dehydrogenase Sord 
-3,7
Mm.139418 sestrin 1  Sesn1 
-3,6
Mm.292168 synuclein, alpha interacting protein (synphilin) Sncaip 
-3,4
Mm.330731 transglutaminase 2, C polypeptide Tgm2 
-3,2
Mm.391736 Transcribed locus  
-3,0
Mm.281639 Rab40b, member RAS oncogene family Rab40b 
-3,0
Mm.388929 angiopoietin-like 7 Angptl7 
-3,0
Mm.311974 expressed sequence AW548124 AW548124 
-3,0
Mm.132237 microtubule-associated protein, RP/EB family, member 2 Mapre2 
-3,0
Mm.284811 unc-119 homolog (C. elegans) Unc119 
-2,9
Mm.386788 protein tyrosine phosphatase-like A domain containing 2 Ptplad2 
-2,9
Mm.293316 RAS-like, family 11, member B Rasl11b 
-2,9
Mm.243802 basonuclin 1 Bnc1 
-2,9
Mm.407415 DNA segment, human D4S114 D0H4S114 
-2,8
Mm.19155 secreted frizzled-related protein 2 Sfrp2 
-2,8
 4
Mm.232525 anthrax toxin receptor 1 Antxr1 
-2,7
Mm.4258 osteoglycin Ogn 
-2,7
Mm.393018 transformation related protein 53 inducible nuclear protein 1 Trp53inp1 
-2,6
Mm.3193 protein kinase inhibitor, alpha Pkia 
-2,6
Mm.3126 four and a half LIM domains 1 Fhl1 
-2,6
Mm.6257 solute carrier family 1 (high affinity aspartate/glutamate transporter), 
member 6 
Slc1a6 
-2,6
Mm.4141 very low density lipoprotein receptor Vldlr 
-2,6
Mm.36416 frizzled homolog 2 (Drosophila) Fzd2 
-2,6
Mm.250841 DNA-damage-inducible transcript 4-like Ddit4l 
-2,6
Mm.14063 dehydrogenase/reductase (SDR family) member 3 Dhrs3 
-2,5
Mm.15295 epoxide hydrolase 2, cytoplasmic Ephx2 
-2,5
Mm.282900 PDZ and LIM domain 3 Pdlim3 
-2,5
Mm.277409 growth factor receptor bound protein 2-associated protein 1 Gab1 
-2,5
Mm.297978 C-fos induced growth factor Figf 
-2,4
Mm.49689 sarcospan Sspn 
-2,4
Mm.40325 zinc finger protein 521 Zfp521 
-2,4
Mm.322738 5-oxoprolinase (ATP-hydrolysing) Oplah 
-2,4
Mm.275003 melanoma cell adhesion molecule Mcam 
-2,3
Mm.4561 matrix metallopeptidase 11 Mmp11 
-2,3
Mm.14313 endothelial-specific receptor tyrosine kinase Tek 
-2,3
Mm.25259 natriuretic peptide receptor 3 Npr3 
-2,3
Mm.335454 WD repeat domain 6 Wdr6 
-2,3
Mm.339812 fibroblast growth factor 18 Fgf18 
-2,3
Mm.112933 a disintegrin-like and metallopeptidase (reprolysin type) with 
thrombospondin type 1 motif, 5 (aggrecanase-2)  
Adamts5 
-2,2
Mm.282985 adaptor protein, phosphotyrosine interaction, PH domain and leucine zipper 
containing 2 
Appl2 
-2,2
Mm.38469 amyloid beta (A4) precursor protein-binding, family B, member 1 Apbb1 
-2,2
Mm.28896 START domain containing 10 Stard10 
-2,2
Mm.224306 kelch-like 13 (Drosophila) Klhl13 
-2,2
Mm.34650 paralemmin Palm 
-2,2
Mm.221403 platelet derived growth factor receptor, alpha polypeptide Pdgfra 
-2,2
Mm.23720 solute carrier family 25 (mitochondrial carrier; phosphate carrier), member 
23 
Slc25a23 
-2,2
Mm.268521 insulin-like growth factor 1 Igf1 
-2,2
Mm.272569 serine (or cysteine) peptidase inhibitor, clade B, member 9 Serpinb9 
-2,2
Mm.426079 interferon-induced protein with tetratricopeptide repeats 3 Ifit3 
-2,1
Mm.87456 DAZ interacting protein 1 Dzip1 
-2,1
Mm.375091 RIKEN cDNA 2310002J21 gene 2310002J21Rik 
-2,1
Mm.30239 solute carrier family 39 (metal ion transporter), member 8 Slc39a8 
-2,1
Mm.245724 acetyl-Coenzyme A acyltransferase 2 (mitochondrial 3-oxoacyl-Coenzyme A 
thiolase) 
Acaa2 
-2,1
Mm.1360 growth arrest and DNA-damage-inducible 45 beta Gadd45b 
-2,1
Mm.7329 guanidinoacetate methyltransferase Gamt 
-2,1
Mm.22216 TSC22 domain family 3 Tsc22d3 
-2,1
Mm.273536 RIKEN cDNA 6720475J19 gene 6720475J19Rik 
-2,1
 5
Mm.1605 programmed cell death 4 Pdcd4 
-2,1
Mm.221275 reticulon 1 Rtn1 
-2,1
Mm.1237 peripheral myelin protein Pmp22 
-2,1
Mm.40717 Cdk5 and Abl enzyme substrate 1 Cables1 
-2,1
Mm.19825 RIKEN cDNA 1200015N20 gene 1200015N20Rik 
-2,1
Mm.184021 protein tyrosine phosphatase, receptor type, D Ptprd 
-2,0
Mm.28955 RIKEN cDNA 4930570C03 gene 4930570C03Rik 
-2,0
Mm.231091 dicarbonyl L-xylulose reductase Dcxr 
-2,0
Mm.458098 ATPase, H+ transporting, lysosomal V0 subunit E2 Atp6v0e2 
-2,0
Mm.245851 Cd200 antigen Cd200 
-2,0
Mm.394593 glutathione S-transferase, alpha 3 Gsta3 
-2,0
Mm.260164 hydroxyacyl-Coenzyme A dehydrogenase Hadh 
-2,0
Mm.285075 opioid receptor-like 1 Oprl1 
-2,0
Mm.210815 sorbin and SH3 domain containing 1 Sorbs1 
-2,0
Mm.275414 Transcribed locus  
-2,0
Mm.67949 armadillo repeat containing, X-linked 3 Armcx3 
-2,0
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ary Figure 1. qRT-PCR analysis of selected chemokines in endothelial 
lated by immobilized or soluble FGF2. Microvascular 1G11 cells were 
r 24 hours on FGF2-coated dishes (immobilized FGF2) or stimulated for 24 
0 ng/mL of FGF2 (soluble FGF2) onto non-coated dishes. Total RNA was 
cribed to cDNA and analyzed by real time PCR. Data are presented as the 
atio of each target gene relative to an untreated control. Expression levels 
ized to β-actin gene. The bars show mean values ± SD (n=3). Note that both 
and soluble FGF2 induces upregulation of chemokines Ccl2, Ccl7,Cx3cl1, and 
ilar extent. 







